| dc.contributor.author | Rosales-Klintz, S | en_US |
| dc.contributor.author | Bruchfeld, J | en_US |
| dc.contributor.author | Haas, W | en_US |
| dc.contributor.author | Heldal, E | en_US |
| dc.contributor.author | Houben, RMGJ | en_US |
| dc.contributor.author | van Kessel, F | en_US |
| dc.contributor.author | Mandelbaum, M | en_US |
| dc.contributor.author | Matteelli, A | en_US |
| dc.contributor.author | Migliori, GB | en_US |
| dc.contributor.author | Oordt-Speets, A | en_US |
| dc.contributor.author | Solovic, I | en_US |
| dc.contributor.author | Vašáková, M | en_US |
| dc.contributor.author | Verver, S | en_US |
| dc.contributor.author | de Vlas, SJ | en_US |
| dc.contributor.author | Vonk Noordegraaf-Schouten, MJM | en_US |
| dc.contributor.author | de Vries, G | en_US |
| dc.contributor.author | Zenner, D | en_US |
| dc.contributor.author | van der Werf, MJ | en_US |
| dc.date.accessioned | 2020-09-09T15:53:00Z | |
| dc.date.available | 2018-11-09 | en_US |
| dc.date.issued | 2019-01 | en_US |
| dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/66920 | |
| dc.language | eng | en_US |
| dc.relation.ispartof | Eur Respir J | en_US |
| dc.subject | Antitubercular Agents | en_US |
| dc.subject | European Union | en_US |
| dc.subject | Humans | en_US |
| dc.subject | Latent Tuberculosis | en_US |
| dc.subject | Practice Guidelines as Topic | en_US |
| dc.subject | Program Development | en_US |
| dc.title | Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area. | en_US |
| dc.type | Article | |
| dc.identifier.doi | 10.1183/13993003.02077-2018 | en_US |
| pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/30655449 | en_US |
| pubs.issue | 1 | en_US |
| pubs.notes | Not known | en_US |
| pubs.publication-status | Published online | en_US |
| pubs.volume | 53 | en_US |
| dcterms.dateAccepted | 2018-11-09 | en_US |
